COmplementary Nursing in Gynaecologic Oncology-study

Not Applicable

• Conditions: C50-C50; C51-C58; Malignant neoplasm of breast; Malignant neoplasms of female genital organs

• Registration Number: DRKS00006056
• Lead Sponsor: Abteilung Allgemeinmedizin und VersorgungsforschungUniversitätsklinikum Heidelberg

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Start: 2014-04-15
• Last Update Posted: 19 August 2024

Recruitment & Eligibility

• Status: Complete
• Sex: Female
• Target Recruitment: 297

Inclusion Criteria

All female patients diagnosed with gynaecologic cancer and scheduled for a new treatment of chemotherapy will be invited for the study.

Exclusion Criteria

< 18 years, gender: male, insufficient knowledge of German

Study & Design

• Study Type: interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Health-related quality of life: measured with the EORTC-QLQ-C30 at time points T1, T2, T3, T4.

Secondary Outcome Measures

Name	Time	Method
Secondary outcomes: Nausea (MAT), fatigue (FACIT-F), pain (VAS), anxiety/depression (PHQ-9), social support (F-SozU-K14), self-efficacy (SES6G), patient competence (FEPK 2-57), spiritual wellbeing (Sp-REUK-15), patient satisfaction (EORTC-QLQ-PATSAT32) and health economic data (Mannheimer Modul RV) will be analysed at T1 (start of chemotherapy), T2 (midline), T3 (end of Treatment) and T4 (6 months after Treatment).<br>Quality of life of patients' caregivers (WHOQOL-BREF) will be collected at time-points T1, T3, and T4.